Recordati : Carefully selected investment to drive growth
>Sales momentum still on the agenda at end- 2019 - Recordati reported its preliminary 2019 results on Friday, 14 February. The top line rose by 9.6% to € 1.48bn (+0.7% vs the consensus), EBITDA came in at € 544m (+ 9% y-o-y, +0.2% vs consensus), with net profit of 11.5%, ahead of expectations at € 369m (+18.1% y-o-y), benefiting from a positive one-off tax of € 27m. Growth is mainly driven by the group’s leading drug Zanidip (+11.3%) and by the rare diseases franchis...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.